Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 72.

Marzel, A; Shilaih, Mohaned; Turk, T; Campbell, Nottania K; Yang, Wan-Lin; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Calmy, A; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Metzner, K J; Gunthard, H F; Kouyos, R D; Swiss HIV Cohort Study (SHCS), et al (2017). Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships. HIV Medicine, 18(9):667-676.

Meinel, D M; Kuehl, R; Zbinden, R; Boskova, V; Garzoni, C; Fadini, D; Dolina, M; Blümel, B; Weibel, T; Tschudin-Sutter, S; Widmer, A F; Bielicki, J A; Dierig, A; Heininger, U; Konrad, R; Berger, A; Hinic, V; Goldenberger, D; Blaich, A; Stadler, T; Battegay, M; Sing, A; Egli, A (2016). Outbreak investigation for toxigenic Corynebacterium diphtheriae wound infections in refugees from Northeast Africa and Syria in Switzerland and Germany by whole genome sequencing. Clinical Microbiology and Infection, 22(12):1003.e1-1003.e8.

Bader, J; Schöni-Affolter, F; Böni, Jürg; Gorgievski-Hrisoho, M; Martinetti, G; Battegay, M; Klimkait, T (2016). Correlating HIV tropism with immunological response under combination antiretroviral therapy. HIV Medicine, 17(8):615-622.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Fehr, J; Nicca, D; Langewitz, W; Haerry, D; Battegay, M (2015). Assessing HIV-positive Persons’ Readiness to Start and Maintain ART. In: Ryom, L. EACS Guidelines. Brussels: EACS, 22-25.

Letang, E; Muller, M C; Ntamatungiro, A J; Kimera, N; Faini, D; Furrer, H; Battegay, M; Tanner, M; Hatz, Christoph; Boulware, D R; Glass, T R (2015). Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infectious Diseases, 2(2):ofv046.

Weber, R; Huber, M; Battegay, M; Stähelin, C; Castro Batanjer, E; Calmy, A; Bregenzer, A; Bernasconi, E; Schoeni-Affolter, F; Ledergerber, B (2015). Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study. HIV Medicine, 16(3):137-151.

Kouyos, R D; Rauch, A; Braun, D L; Yang, W-L; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Shah, C; Kovari, H; Calmy, A; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Gunthard, H F (2014). Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. Journal of Infectious Diseases, 210(10):1555-1561.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Fehr, J; Nicca, D; Langewitz, W; Haerry, D; Battegay, M (2013). Assessing HIV-positive persons' readiness to start and maintain ART. In: European AIDS Clinical Society. Guidelines of the European AIDS Clinical Society. Paris/France: European AIDS Clinical Society, 6.

Weber, R; Ruppik, M; Rickenbach, M; Spoerri, A; Furrer, H; Battegay, M; Cavassini, M; Calmy, A; Bernasconi, E; Schmid, P; Flepp, M; Kowalska, J; Ledergerber, B; Schmid, P; Schultze, D; Schöni-Affolter, F; Schüpbach, J; Speck, R; Taffé, P; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S (2013). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Medicine, 14(4):195-207.

Gasser, O; Brander, C; Wolbers, M; Brown, N; Rauch, A; Günthard, H; Battegay, M; Hess, C (2013). Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy. HIV Medicine, 14(4):241-246.

Stern, M; Czaja, K; Rauch, A; Rickenbach, M; Günthard, H F; Battegay, M; Fellay, J; Hirschel, B; Hess, C (2012). HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption. HIV Medicine, 13(10):589-595.

von Wyl, V; Yerly, S; Böni, J; Shah, C; Cellerai, C; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Ledergerber, B; Günthard, H F (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clinical Infectious Diseases, 54(1):131-140.

Clifford, G M; Lise, M; Franceschi, S; Egger, M; Bouchardy, C; Korol, D; Levi, F; Ess, S; Jundt, G; Wandeler, G; Fehr, J; Schmid, P; Battegay, M; Bernasconi, E; Cavassini, M; Calmy, A; Keiser, O; Schöni-Affolter, F (2012). Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. British Journal of Cancer, 106(3):447-452.

Fenner, L; Gagneux, S; Helbling, P; Battegay, M; Rieder, H L; Pfyffer, G E; Zwahlen, M; Furrer, H; Siegrist, H H; Fehr, J; Dolina, M; Calmy, A; Stucki, D; Jaton, K; Janssens, J P; Stalder, J M; Bodmer, T; Ninet, B; Böttger, E C; Egger, M (2012). Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: Role of immigration and HIV infection. Journal of Clinical Microbiology, 50(2):388-395.

Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7):387-397.

Wandeler, G; Keiser, O; Hirschel, B; Günthard, H F; Bernasconi, E; Battegay, M; Clerc, O; Vernazza, P L; Furrer, H (2011). A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PLoS ONE, 6(12):e27903.

Marzolini, C; Back, D; Weber, R; Furrer, H; Cavassini, M; Calmy, A; Vernazza, P; Bernasconi, E; Khoo, S; Battegay, M; Elzi, L (2011). Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 66(9):2107-2111.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Rieder, P; Joos, B; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Rauch, A; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clinical Infectious Diseases, 52(4):532-539.

Rotger, M; Dalmau, J; Rauch, A; McLaren, P; Bosinger, S E; Martinez, R; Sandler, N G; Roque, A; Liebner, J; Battegay, M; Bernasconi, E; Descombes, P; Erkizia, I; Fellay, J; Hirschel, B; Miró, J M; Palou, E; Hoffmann, M; Massanella, M; Blanco, J; Woods, M; Günthard, H F; de Bakker, P; Douek, D C; Silvestri, G; Martinez-Picado, J; Telenti, A (2011). Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 121(6):2391-2400.

von Wyl, V; Gianella, S; Fischer, M; Niederoest, B; Kuster, H; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE, 6(11):e27463.

Gianella, S; von Wyl, V; Fischer, M; Niederoest, B; Battegay, M; Bernasconi, E; Cavassini, M; Rauch, A; Hirschel, B; Vernazza, P; Weber, R; Joos, B; Günthard, H F (2011). Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antiviral Therapy, 16(4):535-545.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

di Iulio, J; Ciuffi, A; Fitzmaurice, K; Kelleher, D; Rotger, M; Fellay, J; Martinez, R; Pulit, S; Furrer, H; Günthard, H F; Battegay, M; Bernasconi, E; Schmid, P; Hirschel, B; Barnes, E; Klenerman, P; Telenti, A; Rauch, A (2011). Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology, 53(5):1446-1454.

Mossdorf, E; Stoeckle, M; Mwaigomole, E G; Chiweka, E; Kibatala, P L; Geubbels, E; Urassa, H; Abdulla, S; Elzi, L; Tanner, M; Furrer, H; Hatz, C; Battegay, M (2011). Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infectious Diseases, 11:98.

Elzi, L; Steffen, I; Furrer, H; Fehr, J; Cavassini, M; Hirschel, B; Hoffmann, M; Bernasconi, E; Bassetti, S; Battegay, M (2011). Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infectious Diseases, 11:319.

Kaufmann, G R; Elzi, L; Weber, R; Furrer, H; Giulieri, S; Vernazza, P; Bernasconi, E; Hirschel, B; Battegay, M (2011). Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS, 25(4):441-451.

Hasse, B; Ledergerber, B; Furrer, H; Battegay, M; Hirschel, B; Cavassini, M; Bertisch, B; Bernasconi, E; Weber, R (2011). Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases, 53(11):1130-1139.

Fehr, J; Glass, T R; Louvel, S; Hamy, F; Hirsch, H H; von Wyl, V; Böni, J; Yerly, S; Bürgisser, P; Cavassini, M; Fux, C A; Hirschel, B; Vernazza, P; Martinetti, G; Bernasconi, E; Günthard, H F; Battegay, M; Bucher, H C; Klimkait, T (2011). Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. Journal of Translational Medicine, 9:14.

Haas, A; Zimmermann, K; Graw, F; Slack, E; Rusert, P; Ledergerber, B; Bossart, W; Weber, R; Thurnheer, M C; Battegay, M; Hirschel, B; Vernazza, P; Patuto, N; Macpherson, A J; Günthard, H F; Oxenius, A (2011). Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. Gut, 60(11):1506-1519.

von Wyl, V; Kouyos, R D; Yerly, S; Böni, J; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Staehelin, C; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2011). The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. Journal of Infectious Diseases, 204(7):1095-1103.

Ledergerber, B; Cavassini, M; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B; Furrer, H; Rickenbach, M; Weber, R (2011). Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study. HIV Medicine, 12(5):279-288.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Glass, T R; Battegay, M; Cavassini, M; De Geest, S; Furrer, H; Vernazza, P L; Hirschel, B; Bernasconi, E; Rickenbach, M; Günthard, H F; Bucher, H C (2010). Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(2):197-203.

Opravil, M; Klimkait, T; Louvel, S; Wolf, E; Battegay, M; Fux, C A; Bernasconi, E; Vogel, M; Speck, R; Weber, R (2010). Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(1):51-58.

Rohrbach, J; Robinson, N; Harcourt, G; Hammond, E; Gaudieri, S; Gorgievski, M; Telenti, A; Keiser, O; Günthard, H F; Hirschel, B; Hoffmann, M; Bernasconi, E; Battegay, M; Furrer, H; Klenerman, P; Rauch, A (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 59(9):1252-1258.

Rauch, A; Kutalik, Z; Descombes, P; Cai, T; Di Iulio, J; Mueller, T; Bochud, M; Battegay, M; Bernasconi, E; Borovicka, J; Colombo, S; Cerny, A; Dufour, J F; Furrer, H; Günthard, H F; Heim, M; Hirschel, B; Malinverni, R; Moradpour, D; Müllhaupt, B; Witteck, A; Beckmann, J S; Berg, T; Bergmann, S; Negro, F; Telenti, A; Bochud, P Y (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4):1338-1338-1345.e7 .

Mossdorf, E; Stoeckle, M; Vincenz, A; Mwaigomole, E G; Chiweka, E; Kibatala, P; Urassa, H; Abdulla, S; Elzi, L; Tanner, M; Furrer, H; Hatz, C; Battegay, M (2010). Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Tropical Medicine & International Health, 15(5):567-573.

Kovari, H; Ledergerber, B; Battegay, M; Rauch, A; Hirschel, B; Foguena, A K; Vernazza, P; Bernasconi, E; Mueller, N J; Weber, R (2010). Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clinical Infectious Diseases, 50(4):502-511.

Audigé, A; Taffé, P; Rickenbach, M; Battegay, M; Vernazza, P; Nadal, D; Speck, R (2010). Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors. AIDS Research and Human Retroviruses, 26(9):997-1005.

Kouyos, R D; von Wyl, V; Yerly, S; Böni, J; Taffé, P; Shah, C; Bürgisser, P; Klimkait, T; Weber, R; Hirschel, B; Cavassini, M; Furrer, H; Battegay, M; Vernazza, P L; Bernasconi, E; Rickenbach, M; Ledergerber, B; Bonhoeffer, S; Günthard, H F (2010). Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. Journal of Infectious Diseases, 201(10):1488-1497.

Koligi, K; Mertz, D; Benz, D; Vogt, T; Bloemberg, G V; Winter, L; Tyndall, A; Battegay, M; Walker, U A (2010). Oligoarthritis durch Tropheryma whipplei „Of bugs and joints“. Der Internist, 52(7):884-888.

Alizon, S; von Wyl, V; Stadler, T; Kouyos, R D; Yerly, S; Hirschel, B; Böni, J; Shah, C; Klimkait, T; Furrer, H; Rauch, A; Vernazza, P L; Bernasconi, E; Battegay, M; Bürgisser, P; Telenti, A; Günthard, H F; Bonhoeffer, S; Swiss HIV Cohort Study (2010). Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathogens, 6(9):e1001123.

Marzolini, C; Elzi, L; Gibbons, S; Weber, R; Fux, C; Furrer, H; Chave, J P; Cavassini, M; Bernasconi, E; Calmy, A; Vernazza, P; Khoo, S; Ledergerber, B; Back, D; Battegay, M (2010). Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 15(3):413-423.

Bucher, H C; Rickenbach, M; Young, J; Glass, T R; Vallet, Y; Bernasconi, E; Cavassini, M; Fux, C; Schiffer, V; Vernazza, P; Weber, R; Battegay, M (2010). Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 15(1):31-40.

Keiser, O; Spoerri, A; Brinkhof, M W G; Hasse, B; Gayet-Ageron, A; Tissot, F; Christen, A; Battegay, M; Schmid, P; Bernasconi, E; Egger, M (2010). Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. American Journal of Psychiatry, 167(2):143-150.

Elzi, L; Marzolini, C; Furrer, H; Ledergerber, B; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Weber, R; Battegay, M (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1):57-65.

Rotger, M; Bayard, C; Taffé, P; Martinez, R; Cavassini, M; Bernasconi, E; Battegay, M; Hirschel, B; Furrer, H; Witteck, A; Weber, R; Ledergerber, B; Telenti, A; Tarr, P E (2009). Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. Circulation: Cardiovascular Genetics, 2(6):621-628.

Elzi, L; Kaufmann, G; Weber, R; Fux, C A; Cavassini, M; Hirschel, B; Vernazza, P; Bernasconi, E; Battegay, M (2009). Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. HIV Clinical Trials, 10(4):207-214.

Clifford, G M; Rickenbach, M; Lise, M; Dal Maso, L; Battegay, M; Bohlius, J; Boffi El Amari, E; Karrer, Urs; Jundt, G; Bordoni, A; Ess, S; Franceschi, S (2009). Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood, 113(23):5737-5742.

Combescure, C; Vallier, N; Ledergerber, B; Cavassini, M; Furrer, H; Rauch, A; Battegay, M; Bernasconi, E; Vernazza, P; Hirschel, B (2009). How reliable is an undetectable viral load? HIV Medicine, 10(8):470-476.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

Khanna, N; Elzi, L; Mueller, N J; Garzoni, C; Cavassini, M; Fux, C A; Vernazza, P; Bernasconi, E; Battegay, M; Hirsch, H H (2009). Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clinical Infectious Diseases, 48(10):1459-1466.

Khanna, N; Wolbers, M; Mueller, N J; Garzoni, C; Du Pasquier, R A; Fux, C A; Vernazza, P; Bernasconi, E; Viscidi, R; Battegay, M; Hirsch, H H (2009). JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. Journal of Virology, 83(9):4404-4411.

von Wyl, V; Yerli, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P; Francioli, P; Bonhoeffer, S; Ledergerber, B; Günthard, H (2009). Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clinical Infectious Diseases, 48(7):979-987.

Conen, A; Fehr, J; Glass, T R; Furrer, H; Weber, R; Vernazza, P; Hirschel, B; Cavassini, M; Bernasconi, E; Bucher, H C; Battegay, M (2009). Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 14(3):349-357.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

Vo, N T T; Ledergerber, B; Keiser, O; Hirschel, B; Furrer, H; Battegay, M; Cavassini, M; Bernasconi, E; Vernazza, P; Weber, R (2008). Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 197(12):1685-1694.

Rauch, A; Nolan, D; Furrer, H; McKinnon, E; John, M; Mallal, S; Gaudieri, S; Günthard, H F; Schmid, P; Battegay, M; Hirschel, B; Telenti, A; James, I (2008). HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clinical Infectious Diseases, 46(12):1921-1925.

HIV Cohort Study, Switzerland; von Wyl, V; Yerly, S; Klimkait, T; Böni, J; Bürgisser, P; Battegay, M; Bernasconi, E; Cavassini, M; Furrer, H; Hirschel, B; Vernazza, P L; Rickenbach, M; Ledergerber, B; Guenthard, H F (2008). Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clinical Infectious Diseases, 46:1299-1309.

Berger, S; Schad, T; von Wyl, V; Ehlert, Ulrike; Zellweger, C; Furrer, H; Regli, D; Ledergerber, B; Battegay, M; Weber, R; Gaab, J; Vernazza, P (2008). Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. AIDS, 22(6):767-775.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Wolbers, M; Bucher, H C; Furrer, H; Rickenbach, M; Cavassini, M; Weber, R; Schmid, P; Bernasconi, E; Hirschel, B; Battegay, M (2008). Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Medicine, 9(6):397-405.

Nguyen, A; Calmy, A; Schiffer, V; Bernasconi, E; Battegay, M; Opravil, M; Evison, J M; Tarr, P E; Schmid, P; Perneger, T; Hirschel, B; Swiss HIV Cohort Study (2008). Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Medicine, 9(3):142-150.

Polesel, J; Clifford, G M; Rickenbach, M; Dal Maso, L; Battegay, M; Bouchardy, C; Furrer, H; Hasse, B; Levi, F; Probst-Hensch, N M; Schmid, P; Franceschi, S (2008). Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS, 22(2):301-306.

Glass, T R; De Geest, S; Hirschel, B; Battegay, M; Furrer, H; Covassini, M; Vernazza, P L; Bernasconi, E; Rickenboch, M; Weber, R; Bucher, H C; Swiss HIV Cohort Study (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13(1):77-85.

von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Battegay, M; Furrer, H; Telenti, A; Hirschel, B; Vernazza, P L; Bernasconi, E; Rickenbach, M; Perrin, L; Ledergerber, B; Günthard, H F; Swiss HIV Cohort Study (2007). Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Archives of Internal Medicine, 167(16):1782-1790.

Sendi, P; Günthard, H F; Simcock, M; Ledergerber, B; Schüpbach, J; Battegay, M (2007). Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE, 2(1):e173.

Simcock, M; Sendi, P; Ledergerber, B; Keller, T; Schüpbach, J; Battegay, M; Günthard, H F (2006). A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off? Antiviral Therapy, 11(3):305-314.

Schüpbach, J; Günthard, H F; Joos, B; Fischer, M B; Böni, J; Tomasik, Z; Yerly, S; Perrin, L; Battegay, M; Furrer, H; Vernazza, P; Bernasconi, E; Hirschel, B (2005). HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40(3):250-256.

Schmid, Margrit; Twisselmann, Wiebke; Jacquat, B J; Ledergerber, B; Battegay, M; Egger, M (1996). Geschlechtsunterschiede im Krankheitsverlauf: Analyse der schweizerischen HIV-Kohortenstudie. Swiss Medical Weekly, 126(51-52):2234-2236.

This list was generated on Sat Nov 18 11:49:54 2017 CET.